Industry Veteran Joins CANbridge Life Sciences Advisory Team


Beijing, China, February 13, 2018 — CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, announced that industry veteran, Michael Glynn, has joined the company’s advisory team, where he will provide leadership, direction and input on the CANbridge commercial strategy and planning as the company prepares for its first commercial launch. 

Mr. Glynn is a seasoned global executive with over 40 years of general management and commercialization experience in Asia Pacific, Japan, the Middle East, Latin America and the United States. Most recently, Mr. Glynn was Senior Vice President, Global Commercial Operations, for Synageva BioPharma, where he managed global commercial infrastructure development and implementation for their rare disease lead product launch. His prior experience covers decades of global commercial strategic, leadership and operations activities in medical products and devices in multiple territories, including at Genzyme Corporation, where he rose to the position of Senior Vice President and Regional President, Japan and Asia Pacific. While at Genzyme, Mr. Glynn directed Genzyme’s Japan-Asia Pacific business, growing $186 million in 2007 to $500 million in 2011. 

Mr. Glynn also held several positions at Boston Scientific Corporation, including  President, Endovations Division, overseeing the development and launch of a new medical device, and Vice President and General Manager, Asia, Middle East, Turkey, as well as Vice President and General Manager, Asia Pacific, where he was responsible for operations in each of those areas.  Mr. Glynn also held various executive positions with healthcare companies in the U.S. and Asia, including the Australian subsidiary of Baxter International, where he was involved in a variety of strategic planning and manufacturing Management roles. 

Mr. Glynn holds a Master of Business Administration from Macquarie University, in Sydney, Australia, and a Diploma in Education and a Bachelor of Science, from the National University of Ireland.

“We are delighted to bring Mike onto the advisory team at this crucial juncture for CANbridge,” said James Xue, PhD, CANbridge Chairman, CEO and President. “His depth-of-experience in commercial strategic planning and operations in the Asia Pacific region, as well as in building and managing a rapidly-growing product portfolio, will be instrumental as we transition to a commercial-stage company. He also brings a rich network of business contacts in the region, which we plan to leverage as we continue to expand.”


About CANbridge Life Sciences

CANbridge Life Sciences, Ltd. is a clinical-staged bio-pharmaceutical company accelerating development and commercialization of specialty healthcare products for serious and critical medical conditions in China and North Asia (Korea and Taiwan).  CANbridge develops partnerships with Western bio-pharmaceutical companies with clinical-stage pharmaceutical, medical device or diagnostic products that are either unavailable in China/North Asia or address medical needs that are underserved in the region. CANbridge also licenses, or obtains exclusive rights to commercialize, drug and device products that are approved in their home markets for commercialization in China and North Asia. 

CANbridge has exclusive rights to develop and commercialize Puma Biotechnology’s NERLYNX® (neratinib) in China, Taiwan, Hong Kong and Macao (collectively, greater China), which was approved by the FDA in 2017 for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy. CANbridge plans to target HER2-positive cancers, including breast and gastric. CANbridge has a license with Apogenix to develop, manufacture and commercialize immune-oncology therapy, APG101, for the treatment of glioblastoma multiforme in China, Macao, Hong Kong and Taiwan, where it is being developed as CAN008, and a world-wide license (ex-North America) with AVEO Oncology to develop, manufacture and commercialize clinical-stage ErbB3 (HER3) inhibitory antibody candidate AV203, renamed by CANbridge as CAN017. CANbridge also has an agreement with EUSA Pharma to commercialize Caphosol® in China for the prevention and treatment of oral mucositis caused by cancer treatments.

Led and backed by a highly-seasoned executive team, with extensive Chinese drug development experience, CANbridge has the capability to select, acquire, develop and commercialize future therapeutics and diagnostics targeting the unmet medical needs of Chinese and East Asian patients with serious or critical conditions.  

CANbridge is privately-held and headquartered in Beijing, China.  For more on CANbridge Life Sciences, please go to



CANbridge Life Sciences

James Xue                                                                    






Deanne Eagle

Planet Communications